Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Artificial intelligence (AI) is transforming pharmacovigilance by enabling faster, more accurate detection of adverse drug reactions (ADRs), enhancing predictive modeling, and streamlining regulatory ...